CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 486 enrolled
Drug / intervention
Enbreldrug
Likely dose
Etanercept as provided in real world practiceAI-extracted
Key inclusion· 4
  • ✓Moderate-to-severe plaque psoriasis
  • ✓Currently receiving etanercept for at least 1 year
  • ✓Have difficult to treat sites at presentation
  • ✓Age 18 years or older
Key exclusion· 2
  • ✕Etanercept use for less than 1 year
  • ✕Prior use of other biological treatments for psoriasis

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04428411
NCT04428411N/ACompleted
CompareCT.gov

The Impact of Difficult to Treat Sites on Biological Treatment Response in Patients With Moderate-to-Severe Plaque Psoriasis

Pfizer·observational·Posted Jun 11, 2020·Updated Oct 25, 2021

In Brief

An observational study evaluating Enbrel for Plaque Psoriasis. Completed, enrolled 486 participants across 1 site.

Detailed Summary

This study is to evaluate available local data in Iraq patients with moderate-to-severe plaque psoriasis on Enbrel treatment with regards to efficacy, treatment for PsO who have difficult to treat sites at presentation.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesIraq
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJun 11, 2020
Enrollment StartJul 5, 2020
Primary CompletionAug 30, 2020
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 6.1 years ago

Interventions

Enbreldrug

As provided in real world practice